Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [31] The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
    Opitz, Christiane A.
    Litzenburger, Ulrike M.
    Opitz, Uta
    Sahm, Felix
    Ochs, Katharina
    Lutz, Christian
    Wick, Wolfgang
    Platten, Michael
    PLOS ONE, 2011, 6 (05):
  • [32] Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors
    Zhou, Ji
    Yu, Li-Zhen
    Fan, Ya-Li
    Guo, Ci-Hao
    Lv, Xiao-Mei
    Zhou, Zhi-Yin
    Huang, Hui-Dan
    Miao, Dong-Dong
    Zhang, Sheng-Peng
    Li, Xin-Yu
    Zhao, Ping-Ping
    Liu, Xiao-Ping
    Hu, Wei-Hua
    Zhangb, Chao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 245
  • [33] A molecular docking strategy for identifying fragment inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1)
    Fung, Simon
    Flanagan, Jack U.
    Squire, Christopher J.
    Palmer, Brian D.
    Ching, Lai-Ming
    CANCER RESEARCH, 2014, 74 (19)
  • [34] Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Williams, David K.
    Markwalder, Jay A.
    Balog, Aaron J.
    Chen, Bin
    Chen, Libing
    Donnell, Jennifer
    Haque, Lauren
    Hart, Amy C.
    Mandal, Sunil K.
    Nation, Andrew
    Shan, Weifang
    Vite, Gregory D.
    Covello, Kelly
    Hunt, John T.
    Jure-Kunkel, Maria N.
    Seitz, Steven P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (04) : 732 - 736
  • [35] Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Lee, Dong-Ho
    Lee, Joo-Youn
    Jeong, Jieun
    Kim, Miok
    Lee, Kyung Won
    Jang, Eunseo
    Ahn, Sunjoo
    Lee, Chang Hoon
    Hwang, Jong Yeon
    MOLECULES, 2017, 22 (11):
  • [36] Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)
    White, Catherine
    McGowan, Meredeth A.
    Zhou, Hua
    Sciammetta, Nunzio
    Fradera, Xavier
    Lim, Jongwon
    Joshi, Elizabeth M.
    Andrews, Christine
    Nickbarg, Elliott B.
    Cowley, Phillip
    Trewick, Sarah
    Augustin, Martin
    von Koeenig, Konstanze
    Lesburg, Charles A.
    Otte, Karin
    Knemeyer, Ian
    Woo, Hyun
    Yu, Wensheng
    Cheng, Mangeng
    Spacciapoli, Peter
    Geda, Prasanthi
    Song, Xuelei
    Smotrov, Nadya
    Curran, Patrick
    Heo, Mee Ra
    Abeywickrema, Pravien
    Miller, J. Richard
    Bennett, David Jonathan
    Han, Yongxin
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04): : 550 - 557
  • [37] A novel class of inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) with potential for the treatment of cancer
    Ching, Lai-Ming
    Palmer, Brian D.
    Tomek, Petr
    Flanagan, Jack U.
    Henare, Kimiora
    CANCER RESEARCH, 2015, 75
  • [38] Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors
    Jin, Fangfang
    Hu, Qiyue
    Fei, Hongbo
    Lv, Hejun
    Wang, Shenglan
    Gui, Bin
    Zhang, Junzhen
    Tu, Wangyang
    Zhang, Yun
    Zhang, Lei
    Wan, Hong
    Zhang, Limin
    Hu, Bin
    Yang, Fanglong
    Bai, Chang
    He, Feng
    Zhang, Lianshan
    Tao, Weikang
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (02): : 195 - 201
  • [39] Novel specific- and dual-tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO) inhibitors for tumor immunotherapy
    Mautino, Mario R.
    Metz, Richard A.
    Jaipuri, Firoz
    Waldo, Jesse
    Kumar, Sanjeev
    Marcinowicz-Flick, Agnieszka
    Potturi, Hima
    Adams, James T.
    Van Allen, Clarissa
    Vahanian, Nicholas N.
    Link, Charles J.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] A distinct non-enzymatic role for Indoleamine-2,3-dioxygenase (IDO)2 vs. IDO1 in autoimmune arthritis
    Peng, Weidan
    Merlo, Lauren M. F.
    DuHadaway, James B.
    Montgomery, James D.
    Murray, Peter J.
    Yeh, Syun-Ru
    Prendergast, George C.
    Muller, Alexander J.
    Mandik-Nayak, Laura
    JOURNAL OF IMMUNOLOGY, 2021, 206